Screener Companies About
Nasdaq:ABP
Healthcare Biotechnology

Abpro Holdings, Inc.

A high-risk, high-potential micro-cap stock characterized by massive cash flow from financing and significant non-operating gains despite current operational losses.

■ Key Metrics

Revenue
$183.0K
Net Income
$-7.2M
Gross Profit
$183.0K
Operating Cash Flow
$-9.0M
Total Assets
$4.7M
Shareholders' Equity
$-14.9M
Cash & Equiv
$2.9M

⚖ Investment Thesis

Bull Case

Investors might buy ABP as a speculative play on potential future monetization of R&D efforts or asset sales funded by the $100M+ capital base. The massive financing cash flow suggests active investor backing or strategic partnership support that could facilitate a turnaround. If the company can transition from non-operating reliance to operational revenue, the current valuation offers significant upside.

Bear Case

The stock is dangerous given a net profit loss of $7.2M and operating profit of nearly -$10M with only $183k in revenue. The business model appears unsustainable as core operations burn through cash while relying entirely on financing inflows to survive. With no significant revenue trend over the last five years, the company lacks the market traction required for long-term survival.

◉ About Abpro Holdings, Inc.

Abpro Holdings Inc. (ABP) is a small-cap technology firm operating with minimal current revenue but significant investment activity. The company reports substantial non-operating income alongside heavy operating losses and has maintained a large paid-in capital base to fund its growth initiatives. While recent years show a sharp decline in profitability, the balance sheet suggests an entity potentially in a pre-revenue or early-stage scaling phase.

⚙ Analysis

Management Discussion

Management is currently absorbing a massive operating loss of $9.0M, heavily subsidized by $11.2M in financing cash flows and non-operating gains. Despite the sharp drop in net income from $2.8M in 2023 to a deficit in 2024, the company maintains a positive net change in cash driven by external capital injections rather than earnings.

Industry Overview

The micro-cap technology sector often rewards bold innovation but penalizes prolonged losses heavily. Companies in this space typically require continuous external funding until they achieve product-market fit or acquire a stable revenue base. Investors must distinguish between companies building future value versus those simply delaying inevitable bankruptcy through financing tricks.

☰ Financial Statements

Income Statement
Balance Sheet
Cash Flow
Metric202220232024
Revenue$0$0$183.0K
Cost of Revenue$0$0$0
Gross Profit$0$0$183.0K
Operating Expenses$2.1M$1.7M$10.1M
Operating Income$-2.1M$-1.7M$-9.9M
R&D——$3.0M
G&A——$7.1M
Stock-Based Comp$362.5K$0$1.9M
D&A——$74.0K
Depreciation——$65.0K
Other OpEx——$0
Non-Operating Income$3.8M$5.7M$2.7M
Interest Income$1.8K$52.3K$9.0K
Pre-Tax Income$1.7M$4.0M$-7.2M
Income Tax$824.0K$1.2M$0
Continuing Ops$886.9K$2.8M$-7.2M
Discontinued Ops$0$0$0
Net Income$886.9K$2.8M$-7.2M
Minority Interest$0$0$0
Net to Common$886.9K$2.8M$-7.2M
Metric202220232024
Current Assets$770.2K$30.0M$3.8M
Cash & Equivalents$392.4K$264.5K$2.9M
Accounts Receivable——$323.0K
Prepaid Expenses——$306.0K
Other Current Assets$377.8K$29.7M$297.0K
Long-Term Assets$309.8M$7.4M$885.0K
PP&E (Net)——$37.0K
Operating Leases——$418.0K
Other LT Assets——$430.0K
Total Assets$310.6M$37.4M$4.7M
Current Liabilities$2.1M$35.4M$19.6M
Accounts Payable——$3.9M
Current Leases——$456.0K
Taxes Payable——$366.0K
Other Current Liab$899.0K$34.9M$7.4M
Long-Term Liabilities$10.5M$10.5M$0
Total Liabilities$12.6M$45.9M$19.6M
Shareholders' Equity$297.9M$-8.5M$-14.9M
Paid-In Capital—$0$100.6M
Retained Earnings$-11.2M$-15.8M$-116.1M
Total L&E$310.6M$37.4M$4.7M
Metric202220232024
Net Income (CFO)$886.9K$2.8M$-7.2M
Non-Cash Adjustments$-4.5M$-5.0M$-1.1M
Working Capital Changes$2.4M$-1.7M$-653.0K
Cash from Operations$-1.2M$-3.8M$-9.0M
Cash from Investing$-305.7M$278.4M$0
Share Buybacks—$276.5M—
Cash from Financing$307.2M$-274.7M$11.2M
FX Effect$0$0$0
Net Change in Cash$392.4K$-127.9K$2.1M
Beginning Cash$0$392.4K$861.0K
Ending Cash$392.4K$264.5K$3.0M

Frequently Asked Questions

How does Abpro Holdings, Inc. make money?

The company's financials suggest a primary segment focused on technology development or asset acquisition given the $3.0M R&D spend and $183k revenue, with secondary segments likely driven by investment income rather than core product sales.

What are the main risks for ABP?

Severe operating loss of $9.0M indicates a lack of sustainable core business profitability. Significant retained earnings deficit of $116.1M suggests prolonged financial distress or heavy historical burn. Heavy reliance on non-operating income and financing cash flow rather than operational cash generation creates fragility. Minimal revenue trend over five years signals high failure risk if scaling does not occur.

What is ABP's competitive advantage?

Significant paid-in capital of over $100M provides deep liquidity for strategic acquisitions or research expansion. The company leverages substantial non-operating income streams which currently subsidize operations. Low current liabilities relative to financing cash inflows indicates strong external support.

Related Companies

Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.